Cocco R R, Järvinen K-M, Han N, Beyer K, Sampson H A
Division of Pediatric Allergy & Immunology and Jaffe Institute for Food Allergy, The Mount Sinai School of Medicine, New York, NY 10029-6574, USA.
Clin Exp Allergy. 2007 Jun;37(6):831-8. doi: 10.1111/j.1365-2222.2007.02712.x.
For immunotherapeutic approaches, 'critical' amino acids (AAs) within allergenic epitopes are replaced with alternate AAs to eliminate IgE antibody binding.
To determine the critical AAs for IgE binding in beta-casein and beta-lactoglobulin (BLG).
Peptides of 10-14 AAs in length were synthesized on a derivatized cellulose membrane with single AA substitutions (alanine or glycine) at each position. Membranes were incubated with a pool of sera from 15 cow's milk-allergic patients and individual sera from six of the 15 patients. In cases where no decrease in binding occurred with a single AA substitution, peptides with two AA substitutions were generated and labelled.
Using pooled patient sera, single AA substitutions led to complete elimination of binding to six of 11 peptides for beta-casein and to all six peptides for BLG. Substituting two AAs led to an elimination of binding to four of the remaining five beta-casein epitopes. However, in three of the 11 modified beta-casein peptides and five of the six BLG peptides, no decrease in IgE binding occurred in at least one individual patient. For these patients, critical AAs other than those defined by the patient serum pool were identified, indicating a heterogeneous pattern of IgE recognition.
These results indicate that AAs critical for IgE binding are more heterogeneous than initially defined by pooled milk-allergic patient sera. For future immunotherapeutic interventions with mutated peptides, critical AAs should also be identified with individual patient sera to account for heterogeneity of IgE binding between patients.
对于免疫治疗方法,变应原表位内的“关键”氨基酸(AA)被替换为替代氨基酸以消除IgE抗体结合。
确定β-酪蛋白和β-乳球蛋白(BLG)中与IgE结合的关键氨基酸。
在衍生化的纤维素膜上合成长度为10 - 14个氨基酸的肽,每个位置进行单个氨基酸替换(丙氨酸或甘氨酸)。将膜与15名牛奶过敏患者的混合血清以及15名患者中6名患者的个体血清一起孵育。在单个氨基酸替换后结合未减少的情况下,生成并标记具有两个氨基酸替换的肽。
使用患者混合血清,单个氨基酸替换导致β-酪蛋白的11种肽中的6种以及BLG的所有6种肽的结合完全消除。替换两个氨基酸导致其余5种β-酪蛋白表位中的4种的结合消除。然而,在11种修饰的β-酪蛋白肽中的3种和6种BLG肽中的5种中,至少在一名个体患者中IgE结合没有减少。对于这些患者,鉴定出了患者血清池定义之外的关键氨基酸,表明IgE识别模式存在异质性。
这些结果表明,与IgE结合关键的氨基酸比最初由牛奶过敏患者混合血清定义的更加异质。对于未来使用突变肽的免疫治疗干预,也应使用个体患者血清鉴定关键氨基酸,以考虑患者之间IgE结合的异质性。